Clinical Trial

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-06 -> 2026-08 2026-06-06
minor Completion pushed: 2026-06 -> 2026-08 2026-06-06
critical Recruitment opened 2026-05-06
Trial Details
NCT Number NCT07539090
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Healthy Participants
Enrollment 24 participants
Start Date 2026-06-05
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-17